In this study, we performed a comprehensive phenotypic and clonotypic assessment of expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations in T-LGLL and dasatinib-treated CML patients. This evidence concerns the gene CD8A and chronic myelogenous leukemia, BCR-ABL1 positive.